Broser® (bromelain, escin and selenium), oral nutraceutical, monotherapy in patients with inflammatory otorhinolaryngological disorders

Abstract

Inflammation is a common pathogenic mechanism involved in many otorhinolaryngological (ORL)disorders. Broser® is an oral nutraceutical currently containing bromelain 100 mg, escin 30 mg, andselenium 42.5 mcg. It could exert a safe and effective anti-inflammatory activity by virtue of thesecomponents. Therefore, the aim of the current survey, conducted in clinical practice of 84 Italian ORLcenters, was to evaluate its safety and efficacy in the treatment of patients with: i) high-tract acute illness;ii) low-tract acute illness; iii) high-tract chronic illness; iv) low-tract chronic illness; or v) post-surgerycondition. The 3,203 (1,604 females and 1,599 males, mean age 44.9±8.9 years) patients were evaluatedat baseline (T0) and after a 2-week treatment (T1) with Broser® monotherapy (2 tablets/daily). Signs andsymptom severity were measured by visual analogue scale. Broser® significantly and safely diminishedthe clinical features in ORL disorders all sub-groups (p<0.001 for all). In conclusion, Broser® is an oralnutraceutical able to exert a safe and effective anti-inflammatory activity in patients with inflammation.